Our results revealed PCDHGC3, HLA-B, ITGA4 and LRP1 as major components of ESP protein fraction that accumulates following kifunensine treatment, these proteins having also key-functions in different pathologies such as pancreatic cancer (HLA-B) (Sliker et al., 2020), melanoma and ovarian cancer (ITGA4) (Hoek et al., 2004; Zhu et al., 2020) or Alzheimer disease (LRP1) (Shinohara et al., 2017). The gene discussed is LRP1; the disease is melanoma.